Hook & thesis
Ares Capital (ARCC) trades at $18.53 but is sitting on a near-term re-rating opportunity. Management just agreed to buy MidCap Financial for $10.88 per share in a roughly $2.6 billion cash-and-stock deal that expands Ares’ portfolio, scale, and fee-earning capacity. The market’s tepid reaction to a quarter that missed by a sliver leaves a clean entries-and-stops opportunity: buy ARCC at $18.50 with a $17.60 stop and a $20.50 target over the mid-term (45 trading days).
The bull case is straightforward: the acquisition accelerates scale to a reported ~$31 billion portfolio across 800+ companies, the company continues to cover a $0.48 quarterly dividend (a ~10% yield) with nearly $983 million in spillover income noted by management, and lending spreads are improving. Those facts argue the market is overlooking an operational uplift that should support a multiple expansion back toward near-term moving averages.
Business primer - why the market should care
Ares Capital is a BDC-specialty finance company that provides direct loans and other structured investments to private middle-market U.S. businesses. The model is simple: generate high current income via lending and portfolio income, distribute most of it as dividends, and grow per-share earnings through accretive dealmaking and scale.
Key items to watch that matter to valuation and to the thesis: quarterly distributable earnings, portfolio credit quality, financing costs for new debt issuance, and deal accretion. Ares reported Q3 results on 10/28/2026 showing core EPS of $0.46 (miss vs. consensus $0.48) and revenue of $763 million (a 2.2% miss). Management nonetheless highlighted the MidCap acquisition and a favorable financing environment, including a $750 million unsecured note at a low BDC spread noted in recent commentary.
What the numbers say
- Price: $18.53, market cap roughly $13.3 billion.
- Dividend: $0.48 quarterly, which implies a yield of about 10%.
- Valuation snapshot: price-to-earnings near 14x, price-to-book ~0.96, enterprise value roughly $28.8 billion with EV/EBITDA ~28.7x.
- Credit metrics / returns: return on assets ~3.15%, return on equity ~6.91%, debt-to-equity ~1.14.
- Liquidity / flows: average daily volume ~4.7M shares; short interest ~40M shares (about 9 days to cover) – a sizable, persistent short base to be aware of.
Those figures tell a mixed story. On one hand, P/E and P/B show the market is not paying a growth premium today; on the other hand, EV/EBITDA looks rich relative to those multiples, reflecting the capital-intensive and leveraged nature of BDCs plus near-term earnings volatility. The critical offset: the company covers a large quarterly distribution and management cites nearly $983 million in spillover income to support that dividend while adding scale through the MidCap deal.
Valuation framing
At ~$18.5 the stock sits below its 50-day moving average (~$19.25) while its 10- and 20-day SMAs are slightly higher than current price, suggesting the market has pushed valuation toward a short-term discount. Price-to-book at ~0.96 says the market values Ares at roughly tangible book; P/E ~14x is compressive for a business that yields 10% and can grow EPS via accretive M&A.
EV/EBITDA ~28.7x is elevated, but that metric can be misleading in BDCs because of accounting nuances around interest and non-cash items. The stronger, more actionable lens here is distributable cash and cash coverage of the dividend. Management’s assertion of $983M in spillover income and the ability to raise $750M at low spreads are tangible forces that ought to support the dividend and derisk headline distribution fear, which is the principal reason BDCs trade wide of traditional financial multiples.
Catalysts (what will drive the trade)
- Close and integration progress on the MidCap deal (expected to close H1 2027) - each affirmative update should be a positive re-rate.
- Management commentary on portfolio credit quality and spillover income at the next monthly/quarterly update - any confirmation of the ~$983M spillover narrative is constructive.
- Evidence of improved lending spreads and stronger new originations - management has noted wider spreads already and every basis-point move helps the BDC model.
- Analyst estimate revisions (Zacks and others have recently moved estimates up) - continued upgrades should push multiples higher.
Trade plan (actionable)
Trade direction: long.
Entry price: $18.50. Exact entry for the order: 18.50.
Stop loss: $17.60. Exact stop for the order: 17.60. Place a hard stop or an alert to reassess if $17.60 is hit; that level sits below recent intraday lows and below the 20-day EMA, invalidating the short-term bounce thesis.
Target price: $20.50. Exact limit for the exit: 20.50. This target brings the stock back toward the 50-day SMA and implies roughly +11% from entry while maintaining a favorable risk/reward.
Horizon: mid term (45 trading days). I expect the catalyst window to play out over weeks as markets digest MidCap integration details, dividend coverage updates, and any further positive spread commentary. If the acquisition process triggers clear accretion or the company reports incremental financing wins, realize gains into the $20.50 area.
Risk/reward: entry to target is +$2.00; entry to stop is -$0.90. Reward-to-risk is ~2.2x. Position size should be calibrated to individual risk tolerance and intent to hold through corporate newsflow.
Risks and counterarguments (what could go wrong)
- Dividend pressure / credit deterioration - although management cites spillover income (~$983M), a deterioration in portfolio credit or a larger-than-expected increase in non-accruals would force dividend cuts and collapse the valuation quickly.
- Integration and acquisition risk - MidCap was noted to have recent earnings weakness and a dividend cut; Ares’ acquisition could bring legacy credit problems on its books, yielding surprises in provisioning and near-term EPS dilution.
- Macro / rates volatility - BDCs are sensitive to the lending environment and financing costs. A sudden spike in rates or a widening of BDC debt spreads would harm net interest margins and valuation.
- Execution risk on accretion claims - management projects accretion and scale benefits, but if deal synergies lag or financing terms worsen, the promised lift to core EPS may not materialize.
- Market technical risk - heavy short interest (~40M shares) means the stock can experience sharp moves; that can amplify volatility and hit stops on intraday swings even if fundamentals remain intact.
Counterarguments I respect: the company missed on EPS and revenues this quarter, which argues the business has near-term operational pressure and that the market’s caution is warranted. Free cash flow was reported negative (-$680 million), and EV/EBITDA looks high relative to the compressed P/E and P/B — a sign that headline enterprise multiples are pricing in future earnings or credit deterioration. Those points justify a cautious position size and the use of a stop to protect capital.
What would change my mind
If I’m wrong, the following developments would force me to close the trade early or flip the thesis to neutral/short:
- Any official announcement that dividend coverage has materially worsened or management reduces the quarterly distribution.
- Signs of accelerating non-accruals or credit losses tied to the MidCap portfolio that materially increase provisioning expectations.
- Failure to secure favorable financing terms for the transaction or a sudden widening of BDC debt spreads that compresses net investment income.
Conclusion - clear stance
Trade idea: go long ARCC at $18.50 with a $17.60 stop and a $20.50 target, mid-term (45 trading days). The trade rests on three practical pillars: an accretive, scale-building MidCap acquisition; management’s public assertion of meaningful spillover income backing a 10%-plus dividend; and a lending environment that management says is beginning to reward originators with wider spreads. Those dynamics argue for a re-rate toward the 50-day range if the company’s guidance and deal integration checks out.
Keep position sizing disciplined. This is a mid-term swing trade that leans on corporate execution rather than a long-term buy-and-hold thesis. If the dividend narrative or credit quality turns, step aside quickly and reassess.